RSV Disease Threat and Innovative Prevention Methods in Health Protection: A Review
DOI:
https://doi.org/10.12775/JEHS.2024.61.003Keywords
Respiratory syncytial virus (RSV), Bronchitis, RSV prevention, Palivizumab, Nirsevimab, RSV vaccineAbstract
Respiratory syncytial virus (RSV) causes infections of the lower respiratory tract. A group particularly vulnerable to severe infection are young children under 2 years of age and the elderly. The infection can cause the entire spectrum of respiratory symptoms from upper respiratory tract infections to severe courses requiring assisted breathing. Until recently, the only form of protection against infection was passive immunization, i.e. administration of immunoglobulins. Chief among these are palivizumab and nirsevimab. In May u June 2023, the Food and Drug Administration (FDA) approved for use 2 vaccines against RSV are Arexvy and Abrysvo. In this study, we focus on presenting and describing the clinical evidence supporting the effectiveness of these immunization methods.
References
Simoes EA. Respiratory syncytial virus infection. Lancet. 1999;354(9181):847-852. doi:10.1016/s0140-6736(99)80040-3.
Wildenbeest JG, Billard MN, Zuurbier RP, et al. The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study. Lancet Respir Med. 2022. doi:10.1016/s2213-2600(22)00414-3.
Jain S, Williams DJ, Arnold SR, et al. Community-Acquired pneumonia requiring hospitalization among U.S. children. New Engl J Med. 2015;372(9):835-845. doi:10.1056/nejmoa1405870.
Dowell SF, Anderson LJ, Gary HE, et al. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J Infect Dis. 1996;174(3):456-462. doi:10.1093/infdis/174.3.456
Widmer K, Zhu Y, Williams JV, Griffin MR, Edwards KM, Talbot HK. Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults. J Infect Dis. 2012;206(1):56-62. doi:10.1093/infdis/jis309.
Collins PL, Fearns R, Graham BS. Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease. Curr Top Microbiol Immunol. 2013;372:3-38. doi:10.1007/978-3-642-38919-1_1
Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140(6):543-546. doi:10.1001/archpedi.1986.02140200053026
Fuentes S, Coyle EM, Beeler J, Golding H, Khurana S. Antigenic fingerprinting following primary RSV infection in young children identifies novel antigenic sites and reveals unlinked evolution of human antibody repertoires to fusion and attachment glycoproteins. PLOS Pathog. 2016;12(4):e1005554. doi:10.1371/journal.ppat.1005554.
Jiang MY, Duan YP, Tong XL, et al. Clinical manifestations of respiratory syncytial virus infection and the risk of wheezing and recurrent wheezing illness: a systematic review and meta-analysis. World J Pediatr. 2023. doi:10.1007/s12519-023-00743-5.
Sawyer MH, Barnett E, Lynfield R, Kimberlin DW. Red Book 2021: Report of the Committee on Infectious Diseases. American Academy of Pediatrics; 2021.
Marlow R, Finn A, Henderson J. Assessing the association between bronchiolitis in infancy and recurrent wheeze: a whole English birth cohort case–control study. Thorax. 2019;74(5):503-505. doi:10.1136/thoraxjnl-2018-212203.
Simões EA, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick L, Groothuis JR. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. J Allergy Clin Immunol. 2010;126(2):256-262. doi:10.1016/j.jaci.2010.05.026.
Sigurs N, Aljassim F, Kjellman B, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax. 2010;65(12):1045-1052. doi:10.1136/thx.2009.121582.
Piedimonte G. Pathophysiological mechanisms for the respiratory syncytial virus-reactive airway disease link. Respir Res. 2002;3(S1). doi:10.1186/rr185.
Fauroux B, Simões EA, Checchia PA, et al. The burden and long-term respiratory morbidity associated with respiratory syncytial virus infection in early childhood. Infect Dis Ther. 2017;6(2):173-197. doi:10.1007/s40121-017-0151-4.
Walker GJ, Foster CS, Sevendal A, et al. Clinical, genomic, and immunological characterization of RSV surge in sydney, australia, 2022. Pediatrics. 2024. doi:10.1542/peds.2023-063667.
Iofrío de Arce A, Álvarez García FJ. Nirsevimab and other strategies for the prevention of RSV infection. An Pediatr (Engl Ed). 2023. doi:10.1016/j.anpede.2023.09.007.
Schepp RM, Kaczorowska J, van Gageldonk PG, et al. Effect of palivizumab prophylaxis on respiratory syncytial virus infection in very preterm infants in the first year of life in the netherlands. Vaccines. 2023;11(12):1807. doi:10.3390/vaccines11121807.
Garegnani L, Roson Rodriguez P, Escobar Liquitay CM, Esteban I, Franco JV. Palivizumab for preventing respiratory syncytial virus (RSV) infection in children. Cochrane Database Syst Rev. 2020. doi:10.1002/14651858.cd013757.
Mazur NI, Löwensteyn YN, Terstappen J, et al. Daily intranasal palivizumab to prevent respiratory syncytial virus infection in healthy preterm infants: a phase 1/2b randomized placebo-controlled trial. eClinicalMedicine. 2023;66:102324. doi:10.1016/j.eclinm.2023.102324.
Boyoglu-Barnum S, Chirkova T, Anderson LJ. Biology of Infection and Disease Pathogenesis to Guide RSV Vaccine Development. Front Immunol. 2019;10. doi:10.3389/fimmu.2019.01675.
Keam SJ. Nirsevimab: First Approval. Drugs. 2022. doi:10.1007/s40265-022-01829-6.
Drysdale SB, Cathie K, Flamein F, et al. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants. New Engl J Med. 2023;389(26):2425-2435. doi:10.1056/nejmoa2309189.
Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. New Engl J Med. 2022;386(9):837-846. doi:10.1056/nejmoa21102755.
Wilkins D, Yuan Y, Chang Y, et al. Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants. Nat Med. 2023. doi:10.1038/s41591-023-02316-5.
Venkatesan P. First RSV vaccine approvals. Lancet Microbe. 2023. doi:10.1016/s2666-5247(23)00195-7.
Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (rs) virus infection in children previously vaccinated with an inactivated rs virus vaccine. Am J Epidemiology. 1969;89(4):405-421. doi:10.1093/oxfordjournals.aje.a120954.
Topalidou X, Kalergis AM, Papazisis G. Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines. Pathogens. 2023;12(10):1259. doi:10.3390/pathogens12101259.
Mejias A, Rodríguez-Fernández R, Oliva S, Peeples ME, Ramilo O. The journey to a respiratory syncytial virus vaccine. Ann Allergy Asthma Amp Immunol. 2020;125(1):36-46. doi:10.1016/j.anai.2020.03.017.
U.S. Food and Drug Administration. Accessed January 15, 2024. https://www.fda.gov/media/168519/download. [(accessed on 15.01.2024)]
Leroux-Roels I, Davis MG, Steenackers K, et al. Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial. J Infect Dis. 2023;227(6):761-772. doi:10.1093/infdis/jiac327.
Leroux-Roels I, Van Ranst M, Vandermeulen C, et al. Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study. J Infect Dis. Published online September 12, 2023. doi:10.1093/infdis/jiad321.
Schwarz TF, Hwang SJ, Ylisastigui PP, et al. 119. Safety and Reactogenicity of an Investigational Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine for Adults ≥ 60 Years of Age (RSVPreF3 OA): an Interim Analysis at 6 Months after Vaccination. Open Forum Infect Dis. 2022;9(Supplement_2). doi:10.1093/ofid/ofac492.197.
Papi A, Ison MG, Langley JM, et al. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. New Engl J Med. 2023;388(7):595-608. doi:10.1056/nejmoa2209604.
ABRYSVO. U.S. Food and Drug Administration. Accessed January 20, 2024. http://www.fda.gov/vaccines-blood-biologics/abrysvo
Falsey AR, Walsh EE, Scott DA, et al. Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine. J Infect Dis. 2021. doi:10.1093/infdis/jiab611.
Peterson JT, Zareba AM, Fitz-Patrick D, et al. Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine. J Infect Dis. 2021. doi:10.1093/infdis/jiab505.
Schmoele-Thoma B, Zareba AM, Jiang Q, et al. Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study. New Engl J Med. 2022;386(25):2377-2386. doi:10.1056/nejmoa2116154.
Simões EA, Center KJ, Tita AT, et al. Prefusion F Protein–Based Respiratory Syncytial Virus Immunization in Pregnancy. New Engl J Med. 2022;386(17):1615-1626. doi:10.1056/nejmoa2106062.
Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate. Pfizer. Accessed January 21, 2024. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-data-phase-3-global
Kampmann B, Madhi SA, Munjal I, et al. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. New Engl J Med. 2023. doi:10.1056/nejmoa2216480.
Walsh EE, Pérez Marc G, Zareba AM, et al. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. New Engl J Med. 2023. doi:10.1056/nejmoa2213836
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Paulina Dąbrowska, Michał Żuber, Karol Bochyński, Katarzyna Molenda, Katarzyna Ciuba, Barbara Borodziuk, Filip Borodziuk, Michał Dacka, Kamila Giżewska, Konrad Białogłowski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 404
Number of citations: 0
